ABSTRACT
INTRODUCTION

38
The last 50 years have seen the emergence of several virulent wildlife pathogens with broad host 39 ranges (Tompkins et al 2015) . These emerging infectious disease (EIDs) have decimated wildlife 40 populations globally, and are a major contributor to the current global loss of biodiversity (e.g. Skerratt 
63
There is currently no cure for this disease in the wild (reviewed in Garner et al 2016) , and given that 
68
Bacterial probiotics represent a promising tool to combat major emerging fungal pathogens in the wild,
69
including Pseudogymnoascus destructans (Hoyt et al 2015) , B. dendrobatidis, and the closely related 70 B. salamandrivorans (Martel et al 2013; . Of these, probiotic research is currently most advanced 
76
To date, most in vitro BdGPL challenge experiments have tested the ability of candidate probiotics to 77 limit the growth just a single isolate of BdGPL. This is problematic because the inhibitory capabilities of 
79
Previous work has found no evidence of a phylogenetic signal in the ability of bacterial genera to 
93
Here we extend previous work to quantify the ability of metabolites from both individual bacteria and Figure 1 ).
108
Bacteria belonged to 10 genera, with 3-11 bacterial isolates per genus (Table S1) 
140
Bacterial consortium challenges
141
Three bacteria were then selected from each of four genera (Acinetobacteria, Chryseobacterium,
142
Serratia, Stenotrophomonas) based on their inhibition profiles; poor to medium inhibitors were 143 selected to determine whether combining these bacteria would improve their inhibitory capabilities.
144
Bacteria were grown individually until turbid and added to fresh tryptone either individually (strains A,
145
B and C of each genus separately), or as a triple (strains A, B and C of each genus together to form 146 single-genus mixes, or a random combination of strains across genera to form multi-genus consortia
147
( 
159
Phylogeny Data: To quantify differences among genera in proportion of BdGPL isolates inhibited
160
(inhibition score >0), we fitted a Binomial GLM with the proportion of the 10 BdGPL isolates each 161 bacterial isolate inhibited as the response, and genus as a fixed effect. We used the quasibinomial
162
error structure as the model was overdispersed (dispersion 6.4), and tested the model containing a
163
genus term with the reduced intercept-only model using a likelihood ratio test.
164
To quantify differences among genera in the degree of inhibition (size of inhibition score), we fitted a
165
hierarchical model in the R package MCMCglmm (Hadfield 2010 ) with the individual inhibition scores
166
of each bacterial isolate (n=58) for each BdGPL isolate (n=10; total n = 580) as a Gaussian response.
167
We fitted both BdGPL isolate, and bacterial strain ID nested within bacterial genus as random effects.
168
We use uninformative, parameter-expanded priors for the random effects as detailed in Hadfield
169
(2010). We ran models for a total of 100,000 iterations following a burn-in of 10,000 iterations and isolates, and the probability that all three probiotic types would yield >50% inhibition.
225 226
RESULTS
227
Phylogenetic Signals of BdGPL Inhibition
228
We assayed the ability of 58 bacterial isolates from 10 genera to modify the growth rates of 10 BdGPL
229
isolates. Mean inhibition scores ranged from100% (complete inhibition of growth) to -225% (strong 230 facilitation of growth). At the genus level, there was no significant variation among genera in mean
231
proportion of BdGPL isolates inhibited (Binomial GLM; 2 9 = 6.2, p=0.72; Table 3 ). Six isolates from
232
five genera showed at least weak inhibition across all 10 BdGPLs, whilst seven isolates from five 233 genera facilitated the growth of all 10 isolates (Supplementary Table S1 ).
234
Variance component analysis revealed considerably more variation in inhibition scores among 235 bacterial strains within genera than among genera themselves (Fig. 1) 
255
MG consortia had a 61% probability of demonstrating stronger inhibition than the mean of their single 256 composite bacterial isolates, which was significantly higher than the corresponding probability for SG for BdGPL SFBC019, where SG consortia had a marginally higher probability of delivering strong 274 inhibition (Fig. 4B) .
275
Finally, we tested the ability of both MG and SG consortia to inhibit the growth of two different B.
276
dendrobatidis isolates in series, as individuals in a single location may be exposed to multiple variants 
309
We detected no phylogenetic signal in the ability of individual bacterial genera to inhibit multiple
310
BdGPL isolates. These data support previous work suggesting the ability to inhibit B. dendrobatidis is 
354
Consortium-Based Approaches to Combatting Fungal Pathogens
355
Our results revealed a positive link between the taxonomic richness of a probiotic consortium and its
356
ability to inhibit B. dendrobatidis growth, but crucially this relationship was highly dependent on B.
357
dendrobatidis isolate. Multi-genus consortia outperformed both single-genus consortia and single 14 bacterial isolates in B. dendrobatidis inhibition, and were far more likely to produce strong inhibition of 359 50% or greater, but only for two of the three pathogen variants.
360
The general relationship between inhibition and consortium diversity was in the expected direction; low 361 community relatedness (i.e. high community dissimilarity) and high species richness both increase the 
374
That B. dendrobatidis isolate can alter the strength of the relationship between consortium diversity 375 and inhibition is a highly novel finding. Our simulated probiotic trials revealed that for two B. 
381
and BdCAPE TF5a1, multi-genus consortia yielded by far the highest probability of observing strong 382 inhibition of 50% or more. That this pattern was not conserved for BdGPL SFBC019 is perhaps the 383 most intriguing finding. As for BdGPL variants JEL423 and AUL2 in the phylogenetic trials, SFBC019
384
was largely resistant to inhibition, with individual bacterial inhibition scores that were often negative.
385
One possible explanation for the lack of efficacy of consortia against SFBC019 is that the when a 
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TABLE LEGENDS
632 Table 1 633
Batrachochytrium dendrobatidis isolates used in the study.
634
635 Table 2 636
Composition of multi-genus consortia used in the study. Single-genus consortia comprised all three 637 bacterial isolates (A, B and C) for a given genus (Acinetobacter, Chryseobacterium, Serratia,
638
Stentrophomonas). 
640
655
Points are conditional modes of the individual BdGPL isolate random effects, marginalised with 656 respect to bacterial isolate. Error bars are 95% credible intervals.
